IPAR

Public Assessment Report for a
Medicinal Product for Human Use

Scientific Discussion

Amikacin 250 mg/ ml Solution for injection/infusion
AMIKACIN SULFATE
PA1418/012/001

The Public Assessment Report reflects the scientific conclusion reached by the Health Products Regulatory Authority (HPRA) at the end of the evaluation process and provides a summary of the grounds for approval of a marketing authorisation for a specific medicinal product for human use. It is made available by the HPRA for information to the public, after deletion of commercially sensitive information. The legal basis for its creation and availability is contained in Article 21 of Directive 2001/83/EC, as amended. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the medicinal product for marketing in Ireland.

CONTENTS

I. INTRODUCTION

Based on the review of the data on quality, safety and efficacy, the HPRA has granted a marketing authorisation for Amikacin 250 mg/ ml Solution for injection/infusion from Athlone Pharmaceuticals Limited on 27th September 2024 for the short-term treatment of serious infections due to susceptible strains.

This was a national generic application. The legal basis for this application is article 10 (3) of Directive 2001/83/EC as amended.

This medicinal product is subject to prescription, which may not be renewed.

The Summary of Product Characteristics (SmPC) for this medicinal product is available on the HPRA's website at www.hpra.ie.

Name of the product	Amikacin 250 mg/ ml Solution for injection/infusion
Name(s) of the active substance(s) (INN)	AMIKACIN
Pharmacotherapeutic classification (ATC code)	J01GB06
Pharmaceutical form and strength(s)	250 mg/ mL Solution for Injection/Infusion
Marketing Authorisation Number(s) in Ireland (PA)	PA1418/012/001
Marketing Authorisation Holder	Athlone Pharmaceuticals Limited

II. QUALITY ASPECTS

II.1. Introduction

This application is for Amikacin 250 mg/ ml Solution for injection/infusion.

II.2 Drug substance

The active substance is Amikacin as Amikacin Sulphate Ph. Eur., an established active substance described in the European Pharmacopoeia, and is manufactured in accordance with the principles of Good Manufacturing Practice (GMP)

The active substance specification is considered adequate to control the quality and meets current pharmacopoeial requirements. Batch analytical data demonstrating compliance with this specification has been provided.

II.3 Medicinal product

P.1 Composition

The medicinal product contains 2 ml of amikacin sulphate equivalent to 500 mg of amikacin (250 mg/ ml).

The excipients in the medicinal product are listed in section 6.1 of the SmPC.
A visual description of the product is included in section 3 of the SmPC.

P.2 Pharmaceutical Development

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

P.3 Manufacture of the Product

The product is manufactured in accordance with the principles of good manufacturing practice (GMP) at suitably qualified manufacturing sites.

The manufacturing process has been validated according to relevant European/ICH guidelines and the process is considered to be sufficiently validated.

P.4 Control of Other Substances (Excipients)

All ingredients comply with Ph. Eur. or are adequately controlled by the manufacturer's specifications.

P.5 Control of Finished Product

The Finished Product Specification is based on the pharmacopoeial monograph for parenteral dosage form, and the tests and control limits are considered appropriate for this type of product.

The analytical methods used are described in sufficient detail and are supported by validation data.

Batch analytical data for a number of batches from the proposed production site(s) have been provided, and demonstrate the ability of the manufacturer to produce batches of finished product of consistent quality.

P.6 Packaging material

The approved packaging for this product is described in section 6.5 of the SmPC.

Evidence has been provided that the packaging complies with Ph. Eur./EU legislation.

P.7 Stability of the Finished Product

Stability data on the finished product in the proposed packaging have been provided in accordance with EU guidelines and support the shelf-life and storage conditions listed in sections 6.3 and 6.4 of the SmPC.

II.4 Discussion on Chemical, Pharmaceutical and Biological Aspects

The important quality characteristics of the product are well-defined and controlled. Satisfactory chemical and pharmaceutical documentation has been provided, assuring consistent quality of Amikacin 250 mg/ ml Solution for injection/infusion.

III. NON-CLINICAL ASPECTS

III.1 Introduction

This active substance has been available on the Irish market for 46 years. Preclinical data have been superseded by clinical experience. No new preclinical data have been submitted. As such, no pre-clinical assessment has been made on the application. This is acceptable for this type of application.

III.2 Ecotoxicity/environmental risk assessment

An Environmental Risk Assessment has not been performed as this product is intended for generic substitution and therefore will not result in an increase of risk to the environment during use, storage and disposal.

III.3 Discussion on the non-clinical aspects

Pharmacodynamic, pharmacokinetic and toxicological properties of Amikcin are well known. As Amikacin is a widely used, well-known active substance, the applicant has not provided additional studies and further studies are not required. Overview based on literature review is, thus, appropriate. The non-clinical overview on the pre-clinical pharmacology, pharmacokinetics and toxicology is adequate. Non-clinical findings are adequately mentioned in the appropriate sections of the SmPC.

IV. CLINICAL ASPECTS

IV.1 Introduction

Amikacin sulfate is a well known active substance with established efficacy and tolerability.

The content of the SmPC approved during the national procedure is comparable with that accepted for the reference product Amikin Injection 100mg/2ml formerly marketed by Bristol Myers Squibb (withdrawn from the market 25.01.2019) and is also comparable with SmPCs for similar products from other procedures.

As this is an intravenous formulation no bioequivalence studies have been conducted.

IV.2 Pharmacokinetics

The pharmacokinetics of amikacin are well characterised.

IV.3 Pharmacodynamics
The pharmacodynamics of amikacin are well characterised.

IV.4 Clinical Efficacy
The efficacy of amikacin is well characterised.

IV.5 Clinical Safety
The safety of amikacin is well characterised.

A Risk Management Plan, version 0.2, dated 01 June 2022 has been submitted, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Amikacin 250mg/ml Solution for Injection (Amikacin Sulfate). It is concluded that routine pharmacovigilance and risk minimisation measures are sufficient.

PSURs shall be submitted in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c (7) of Directive 2001/83/EC and published on the European medicines web-portal. Marketing authorisation holders shall continuously check the European medicines web-portal for the DLP and frequency of submission of the next PSUR.

User test Package leaflet
The applicant submitted a user test conducted using an appropriate methodology in 20 adults. The user test met the predetermined criteria for success. All 20 participants were able to find and understand the relevant information sought in response to the questions included in the user test.

IV.6 Discussion on the clinical aspects
Amikacin is a well-known medicinal product with an established favourable efficacy and safety profile. No clinical studies or bioequivalence/bioavailability studies are considered necessary.

V. OVERALL CONCLUSIONS

Amikacin 250 mg/ mL Solution for Injection/Infusion is a generic form of Amikin Injection 100mg/2ml formerly marketed by Bristol Myers Squibb, which is a well-known medicinal product with a proven chemical-pharmaceutical quality and an established favourable efficacy and safety profile.

Bioequivalence was waived in compliance with the CHMP guidance documents. The SmPC is consistent with that of the reference product and similar products.

The MAH has provided written confirmation that systems and services are in place to ensure compliance with their pharmacovigilance obligations.

The HPRA, on the basis of the data submitted considered that Amikacin 250 mg/ mL Solution for Injection/Infusion has demonstrated a satisfactory risk/benefit profile and therefore granted a marketing authorisation.

VI. REVISION DATE

VII. UPDATES

This section reflects the significant changes following finalisation of the initial procedure.

SCOPE	PROCEDURE NUMBER	PRODUCT INFORMATION AFFECTED	DATE OF START OF PROCEDURE	DATE OF END OF PROCEDURE
New National	CRN008QMH	SmPC, IPAR and PIL		